PUNE, India, September 5, 2016 /PRNewswire/ --
ReportsnReports.com adds Amyloidosis - Pipeline Review, H2 2016
market research report complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The report also covers the
descriptive pharmacological action of the therapeutics, its
complete research and development history and latest news and press
releases. Additionally, the report provides an overview of key
players involved in therapeutic development for Amyloidosis and
features dormant and discontinued projects.
Complete amyloidosis pipeline report spread across 152 pages
talking about 17 companies and 25+ drug profiles as well as
supported with 34 data tables and 16 figures on amyloidosis
industry is now available at
http://www.reportsnreports.com/reports/674738-amyloidosis-pipeline-review-h2-2016.html
.
Companies active and discussed in this 2016 amyloidosis pipeline
research include Alnylam Pharmaceuticals, Inc., Amgen Inc.,
Arcturus Therapeutics, Inc., BELLUS Health Inc, Bsim2, Celgene
Corporation, GlaxoSmithKline Plc, Ionis Pharmaceuticals, Inc.,
Johnson & Johnson, Neurimmune Holding AG, NeuroPhage
Pharmaceuticals, Inc., Oncopeptides AB, Pfizer Inc., Prothena
Corporation Plc, Regeneron Pharmaceuticals, Inc., SOM Innovation
Biotech SL and Takeda Pharmaceutical Company Limited.
Profiles of amyloidosis drugs covered in the report include
ALN-ANG, ALN-TTRsc02, Antisense RNAi Oligonucleotides to Inhibit
Amyloid Precursor Protein for Amyloidosis, carfilzomib, CLR-01,
daratumumab, doxycycline hyclate, EDE-1307, GSK-2315698 +
GSK-2398852, GSK-3039294, inotersen sodium, ixazomib citrate,
LUNAR-TTR, Melflufen , Monoclonal Antibody for Amyloidosis,
Monoclonal Antibody to Inhibit ATTR for Familial Amyloid
Polyneuropathy, Monoclonal Antibody to Target CD66b for Blood
Cancer and Metabolic Disorders, NEOD-001, NI-301, NPT-005,
Oligonucleotides to Inhibit Transthyretin for Amyloidosis,
patisiran , pomalidomide , PRX-004, revusiran , Small Molecules for
AL Amyloidosis, Small Molecules to Inhibit Transthyretin for
Familial Amyloid Polyneuropathy, Small Molecules to Inhibit
Transthyretin Related Amyloid Protein for Familial Amyloidotic
Cardiomyopathy, Small Molecules to Inhibit Transthyretin Related
Amyloid Protein for Familial Amyloidotic Polyneuropathy , tafamidis
meglumine and tolcapone .
Order a copy of Amyloidosis - Pipeline Review, H2 2016 market
research report at
http://www.reportsnreports.com/Purchase.aspx?name=674738 .
Through this report, readers can gain strategically significant
competitor information, analysis, and insights to formulate
effective R&D strategies. Identify emerging players with
potentially strong product portfolio and create effective
counter-strategies to gain competitive advantage in amyloidosis
pipeline. Identify and understand important and diverse types of
therapeutics under development for Amyloidosis. Identify potential
new clients or partners in the target demographic. Develop
strategic initiatives by understanding the focus areas of leading
companies. Plan mergers and acquisitions effectively by identifying
key players and it's most promising pipeline therapeutics. Devise
corrective measures for pipeline projects by understanding
Amyloidosis pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects
to enhance and expand business potential and scope. Modify the
therapeutic portfolio by identifying discontinued projects and
understanding the factors that drove them from Amyloidosis
pipeline.
On a related note, another research titled Amgen Inc.
- Product Pipeline Review - 2016 provides
comprehensive information on the therapeutics under development by
Amgen Inc., complete with analysis by stage of development, drug
target, mechanism of action (MoA), route of administration (RoA)
and molecule type. The report also covers the descriptive
pharmacological action of the therapeutics, its complete research
and development history and the dormant and discontinued projects.
Drug profiles discussed in this Amgen Inc. focused report cover
adalimumab biosimilar, blinatumomab, darbepoetin alfa, denosumab,
etanercept, etelcalcetide hydrochloride, romiplostim, AMG-334,
bevacizumab biosimilar, evolocumab, fulranumab, panitumumab,
rituximab biosimilar, romosozumab, trastuzumab biosimilar,
trebananib, abrilumab, AMG-319, AMG-337, AMG-557, AMG-714, AMG-899,
ganitumab, omecamtiv mecarbil MR, rilotumumab, tezepelumab,
AMG-232, talimogene laherparepvec, AMG-172, AMG-208, AMG-211,
AMG-224, AMG-228, AMG-282, AMG-301, AMG-330, AMG-357, AMG-581,
AMG-592, AMG-595, AMG-780, AMG-811, AMG-820, AMG-876, AMG-900,
AMG-XXX, infliximab biosimilar, pasotuxizumab, solitomab, AM-1638,
AM-3189, AM-6226, AM-7209, AM-8553, AM-9514, AMG-0696, AMG-161,
AMG-1694, AMG-176, AMG-3969, AMG-511, AMG-570, AMG-8718 and
AMG-986. Read more at
http://www.reportsnreports.com/reports/538033-amgen-inc-product-pipeline-review-2016.html
.
Explore more reports on pharmaceuticals market at
http://www.reportsnreports.com/market-research/pharmaceuticals/
.
About Us:
ReportsnReports.com is an online market research reports library
of 500,000+ in-depth studies of over 5000 micro markets. Not
limited to any one industry, ReportsnReports.com offers research
studies on agriculture, energy and power, chemicals, environment,
medical devices, healthcare, food and beverages, water, advanced
materials and much more.
Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
sales@reportsandreports.com
Connect With Us on:
Facebook:https://www.facebook.com/ReportsnReports/
LinkedIn:https://www.linkedin.com/company/reportsnreports
Twitter: https://twitter.com/marketsreports
G+ / Google Plus:
https://plus.google.com/111656568937629536321/posts
RSS/Feeds:
http://www.reportsnreports.com/feed/l-latestreports.xml